Analysis Ocugen Heads to Munich With a $10 Target — and a Shareholder Quorum Still Missing
Ocugen’s leadership is taking its case on the road. The biotech said today that executives will appear at two upcoming industry gatherings, including the “H.C. Wainwright: Biotech on Tap 2026”...